CN102133219A - Anti-cervical cancer effect of oleanolic acid and pharmaceutical preparation thereof - Google Patents
Anti-cervical cancer effect of oleanolic acid and pharmaceutical preparation thereof Download PDFInfo
- Publication number
- CN102133219A CN102133219A CN2010102926552A CN201010292655A CN102133219A CN 102133219 A CN102133219 A CN 102133219A CN 2010102926552 A CN2010102926552 A CN 2010102926552A CN 201010292655 A CN201010292655 A CN 201010292655A CN 102133219 A CN102133219 A CN 102133219A
- Authority
- CN
- China
- Prior art keywords
- oleanolic acid
- cervical cancer
- pharmaceutical preparation
- pharmaceutical
- preparation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 title abstract description 45
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 title abstract description 44
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 title abstract description 44
- 229940100243 oleanolic acid Drugs 0.000 title abstract description 44
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 title abstract description 44
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 title abstract description 43
- 206010008342 Cervix carcinoma Diseases 0.000 title abstract description 17
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 title abstract description 17
- 201000010881 cervical cancer Diseases 0.000 title abstract description 17
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract description 10
- 230000000694 effects Effects 0.000 title abstract description 9
- 239000003814 drug Substances 0.000 abstract description 18
- 206010028980 Neoplasm Diseases 0.000 abstract description 14
- 238000011580 nude mouse model Methods 0.000 abstract description 10
- 241000699660 Mus musculus Species 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 8
- 239000002775 capsule Substances 0.000 abstract description 7
- 238000002347 injection Methods 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 5
- 239000006187 pill Substances 0.000 abstract description 5
- 239000002246 antineoplastic agent Substances 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 239000000284 extract Substances 0.000 abstract description 2
- -1 tables Substances 0.000 abstract description 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 231100001231 less toxic Toxicity 0.000 abstract 1
- 150000002887 oleanolic acids Chemical class 0.000 abstract 1
- 230000001875 tumorinhibitory effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229960002949 fluorouracil Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 208000019065 cervical carcinoma Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000000955 oleanolic acid group Chemical group 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 150000002966 pentacyclic triterpenoids Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241001071804 Gentianaceae Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000795633 Olea <sea slug> Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000977602 Swertia mussotii Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000011162 core material Substances 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a new medical application of oleanolic acid in cervical cancer resistance, and also discloses clinically acceptable pharmaceutical preparations such as tables, capsules, pills, injections and the like which are prepared by using oleanolic acid as a pharmaceutical raw material. The oleanolic acid pharmaceutical preparation of the present invention comprises 1%-99% of oleanolic acids and 99%-1% medicinal excipients (including other compatible drugs). The oleanolic acid and the pharmaceutical preparations thereof provided by the invention have an excellent anti-cervical cancer effect which is represented by significant inhibitory activity against in vitro human cervical cancer cells and significant tumor inhibitory activity against a transplanted tumor in nude mice of the cancer cell. In addition, the active components of the pharmaceutical preparation are traditional Chinese medicine extracts, so the preparation has the advantage of less toxic and side effect than chemotherapeutic drugs.
Description
Technical field
The present invention relates to application and the pharmaceutical preparation thereof of oleanolic acid (Oleanolic acid) aspect anti-cervical cancer, belongs to the field of Chinese medicines.
Background technology
Oleanolic acid (Oleanolic acid) is a pentacyclic triterpenoid, is present in the various plants with the form of episome and glycocide.The main leaf that extracts source Oleaceae plant olive, the Fructus Ligustri Lucidi fruit; Gentianaceae plant Herba Swertiae Mileensis herb, Swertia mussotii Franch.; Leaf, the root of the big star celery of samphire; Wu adds the root bark and the peel of stem of the Zhi Wu of section Cortex araliae chinensis; The big seed Radix Hemsleyae Macrospermae of cucurbitaceous plant, lovely Radix Hemsleyae Macrospermae, the tuber of Chinese Radix Hemsleyae Macrospermae.
The pharmacologic action that oleanolic acid has been reported mainly contains hepatoprotective and falls enzyme, promotes liver cell regeneration, antiinflammatory, heart tonifying, diuresis also have effects such as blood sugar lowering, blood fat reducing, calmness, is the effective ingredient of medicines such as exploitation treatment hepatopathy and blood sugar lowering.We find that in screening antitumor drug process oleanolic acid has the effect of stronger inhibition cervical cancer cell and solid tumor growth thereof.
Before the present invention, do not see with the oleanolic acid to be raw material research pharmaceutical dosage form and the report that is used to prevent and treat the cervical cancer disease.Oleanolic acid is a pentacyclic triterpenoid, and is almost non-toxic, and natural resources of Chinese medicinal materials is very abundant, is a kind of very promising antitumor drug.
The chemical name of oleanolic acid (Oleanolic acid): 3 β-hydroxy-olea-12-en-28-oic acid; Molecular formula C
30H
48O
3Molecular weight: 456.71.
Chemical structural formula:
Summary of the invention
One of purpose of the present invention has provided the pharmaceutical preparation of oleanolic acid;
Two of purpose of the present invention has provided the antineoplastic new usage of oleanolic acid.
The objective of the invention is to be achieved through the following technical solutions:
Pharmaceutical preparation of the present invention contains the oleanolic acid of 1%-99% and the excipient of 99%-1% (medicine that comprises other adapted), preferably contain the oleanolic acid of 20%-80% and the excipient of 80%-20% (medicine that comprises other adapted), preferably contain the oleanolic acid of 60%-70% and the excipient of 40%-30% (medicine that comprises other adapted).
Press practice of pharmacy, oleanolic acid of the present invention can be prepared into the various clinical pharmaceutical dosage form as medicament for resisting cervical cancer, comprise the dosage form of oral formulations or parenterai administration.Said oral formulations selects any in tablet, capsule, pill, granule, microcapsule tablet, suspensoid, drop pill, oral liquid; Said parenterai administration dosage form is selected from a kind of in the middle of injection, aerosol, suppository or the subcutaneous administration dosage form.
Adjuvant in the medicament for resisting cervical cancer of the present invention is meant conventional excipient, as solvent, disintegrating agent, correctives, antiseptic, coloring agent, binding agent etc.The medicine that other compatibility in the antitumor drug of the present invention is used, the oleanolic acid that refers to effective dose is certain medicine material, again compatibility other allowed the Chinese medicine or the chemical drugs that share.
Oleanolic acid pharmaceutical preparation of the present invention has the anti-cervical cancer effect, is to be confirmed by following pharmacodynamics test.
Test example 1 has been investigated the inhibitory action of oleanolic acid to external cervical cancer cell
Cell: human cervical carcinoma's epithelial cell (Hela).For ocean institute of Chinese Academy of Sciences marine drug laboratory provides.
Medicine and reagent: ocean institute of oleanolic acid (Oleanolic acid) Chinese Academy of Sciences marine drug laboratory provides white powder; 5-fluorouracil (5-FU) Nantong elite pharmaceutical Co. Ltd product, lot number is 100402; MTT(SIGMA, USA); DMSO(SIGMA, USA); Trypsin SIGMA, USA); RPMI1640(GIBCO, Invitragen Co., USA); DMEM(GIBCO, Invitragen Co., USA); The top grade hyclone (GIBCO, Invitragen Co., USA); Superfine hyclone Fetal Bovine Serum(Hyclone).
Instrument: ultra cold storage freezer (Nature, USA), cell culture incubator (SANYO, Japan), inverted microscope (NIKON, Japan), microplate reader (Bio-Tek Instruments, Inooski, VT, USA), PH counts (Thermo orion, USA), superclean bench (FLC-Harbin Dong Lian instrument plant).
Experimental technique mtt assay: tumor cell line is gone down to posterity according to the conventional method cultivation, collect the exponential phase cell, regulate concentration of cell suspension 5 * 10
4About individual/ml.Cell suspension is added in 96 well culture plates, and each hole adds 180 μ l.After placing 37 ℃ of constant incubators to cultivate 24 h, experimental group adds each concentration oleanolic acid (with 5-FU as positive controls) 20 μ l/ holes, establishes 4 parallel holes for every group, and establishes blank well (only adding the medicinal solvent of dissolving) with zeroing.37 ℃ of incubators, cultivate 48 h after, with liquid-transfering gun liquid in 96 orifice plates is cleaned every hole, back and adds MTT(1 mg/ml) 30 μ l, put CO
2Incubator is cultivated 4 h for 37 ℃, supernatant discarded, and every hole adds DMSO 150 μ l, puts shaking table and shakes up 30 min, detects under 492 nm with microplate reader, utilizes the SPSS statistical software, calculates cell mortality, asks for IC
50
Result of the test shows, through the SPSS software statistics, the oleanolic acid of variable concentrations has in various degree inhibitory action to the human cervical carcinoma's epithelial cell (Hela) that is used to test, and is certain dose-dependence, and the oleanolic acid of variable concentrations is to suppression ratio, the IC of cervical cancer cell
50Value sees table 1 for details.
The oleanolic acid of table 1 variable concentrations is to the suppression ratio of cervical cancer cell (Hela)
Test example 2 oleanolic acid are to the tumor-inhibiting action of cervical cancer cell transplanted tumor in nude mice
Laboratory animal: the BALB/c nude mice is available from Shanghai Slac Experimental Animal Co., Ltd., and animal licence numbering: SYXK (Shanghai) 2010-0047, totally 20, in 7 ~ 9 ages in week, body weight 20 ~ 22g is male Mus.Animal feeding and experiment are raised in the Affiliated Hospital of Qingdao University Experimental Animal Center for no special pathogen level barrier system.
Tumor cell inoculation: human cervical carcinoma's epithelial cell (Hela) of the trophophase of taking the logarithm is made tumor cell suspension (1 * 10
7Individual/as ml), to implant BALB/c male nude mouse armpit subcutaneous (about 0.3ml/ only), situations such as inoculation back routine observation mice spirit, diet and defecation.After going down to posterity once, with the aseptic taking-up of tumor tissues and be cut into big or small identical 2mm
3Fritter, it is subcutaneous to be seeded in the nude mice armpit with the trocar.
Test grouping and method: the major diameter of vernier caliper measurement tumor nodule (a), minor axis (b), by formula V=a * b
2* 0.52 calculates gross tumor volume, when subcutaneous transplantation tumor length to 100 mm
3After, selecting tumor nude mice of the same size, nude mice is weighed is divided into 3 groups with the table of random number method, is respectively negative control group, positive controls, oleanolic acid group, every group of 5 nude mices.Drug level reaches and specifically is grouped as follows: (1) negative control group: lumbar injection 0.2ml normal saline; (2) positive drug matched group: the 5-FU of lumbar injection 30mg/kg; (3) oleanolic acid group: 40mg/kg lumbar injection.Injection in per 3 days is once injected 10 times continuously, behind last administration 24 h, takes out the tumor piece, and it is heavy to measure tumor, calculates the average tumor suppression ratio at last.Adopt the SPSS software statistics, test data is with (average ± standard deviation) expression, and P is a significant difference significance criterion of meaning less than 0.01.Result of the test sees Table 2.
Table 2 oleanolic acid is to the inhibitory action result of the test of Hela transplanted tumor in nude mice (`X ± SD)
Annotate: compare * * P＜0.01 * P＜0.05 with matched group
By table 2 as seen, the transplanted tumor in nude mice of oleanolic acid treatment group and 5-FU treatment group all has been subjected to inhibition in various degree than matched group, and the oleanolic acid group to the influence of nude mice body weight all less than 1.0%, show that oleanolic acid does not have obvious toxic-side effects.
Above-mentioned isolated test and bulk testing show that oleanolic acid all has the obvious suppression effect to stripped and whole man's cervical cancer cell, and does not have obvious toxic-side effects, and the prompting oleanolic acid is a kind of very promising medicament for resisting cervical cancer.
The specific embodiment
The preparation of embodiment 1 tablet
Oleanolic acid 1000g, medical starch 100g, mix homogeneously is granulated as binding agent with an amount of ethanol, drying, through the pelletizing machine granulate, tabletting, every 0.30g, oral, each 1-2 sheet, twice of every day.
The preparation of embodiment 2 capsules
Oleanolic acid 1000g, medical starch 100g, mix homogeneously is granulated as binding agent with an amount of ethanol, and drying is crossed 120 mesh sieve granulate, dress 0# capsule, every 0.300g, each oral 1-2 grain, twice of every day.
The preparation of embodiment 3 drop pills
Polyethylene Glycol
4000400g, in water-bath, melt, add oleanolic acid raw material 250g, stir, in the impouring insulating tube, regulate thermostat, make medicinal liquid under 80-90 ℃, splash in the liquid paraffin that cooled off (temperature ± 4 ℃), after dripping off, to blot paraffin oil on the pill impouring filter paper, add a small amount of Pulvis Talci again, mixing gets 10000 of Olea acid dropping balls.Oral, one time four, three times on the one, one after each meal.
The preparation of embodiment 4 granules
Oleanolic acid raw material 100g, starch 1000g, Icing Sugar 500g, mix homogeneously is used an amount of alcohol granulation, and drying, granulate, packing are promptly.Oral, a 5g, twice on the one.
The preparation of embodiment 5 microencapsule tablets
Take by weighing stearic acid 12g and 18ml Herba Origani oil respectively as compound recipe capsule material, take by weighing oleanolic acid 80g as capsule core material, by the spray congealing encystation, capsule directly is 10-100 μ m with compressed air.Then with microcapsule and microcrystalline Cellulose mixing, add the mixed encystation material of 12% ethyl cellulose alcoholic solution, make granule by 18 order nylon mesh,, placed exsiccator interior 24 hours in oven dry below 50 ℃, add 1%-3% magnesium stearate tabletting, get the oleanolic acid microencapsule tablet, sheet heavily is 0.4g, and is oral, a 1-2 sheet, twice on the one.
The preparation of embodiment 6 injections
Oleanolic acid 40g, propylene glycol 50ml, PEG400 100ml, water for injection 600ml mixes heating in water bath 30 minutes, add benzyl alcohol 90ml, reuse water for injection adds to 1800ml, handles 10 minutes in ultrasound wave, heats 30 minutes in water-bath again, adjust pH is 5.5-6.5, filter, embedding, sterilization is promptly.Every 3ml, intramuscular injection, a 3ml, twice on the one.
Claims (9)
1. pharmaceutical preparation that is used for the treatment of cervical cancer is characterized in that containing the oleanolic acid for the treatment of effective dose and one or more pharmaceutically acceptable pharmaceutical excipients, or can with the other medicines of oleanolic acid prescription.
2. pharmaceutical preparation according to claim 1, but it is characterized in that containing oleanolic acid and the pharmaceutical excipient of 99%-1% or the medicine of other prescription of 1%-99%.
3. pharmaceutical preparation according to claim 2, but it is characterized in that containing oleanolic acid and the pharmaceutical excipient of 80%-20% or the medicine of other prescription of 20%-80%.
4. pharmaceutical preparation according to claim 3, but it is characterized in that containing oleanolic acid and the pharmaceutical excipient of 40%-30% or the medicine of other prescription of 60%-70%.
5. pharmaceutical preparation according to claim 1 is characterized in that said medicine is the dosage form of oral formulations or parenterai administration.
6. pharmaceutical preparation according to claim 5 is characterized in that said oral formulations is selected from any in tablet, pill, capsule, granule, microcapsule tablet, suspensoid, drop pill, the oral liquid.
7. pharmaceutical preparation according to claim 5 is characterized in that said parenterai administration dosage form is selected from any in the middle of injection, aerosol, suppository or the subcutaneous administration dosage form.
8. the application of oleanolic acid in the preparation medicament for resisting cervical cancer.
9. purposes according to Claim 8 is characterized in that said anti-cervical cancer is meant the growth that suppresses human cervical carcinoma's epithelial cell (Hela) and nude mice transplanted tumor thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102926552A CN102133219A (en) | 2010-09-27 | 2010-09-27 | Anti-cervical cancer effect of oleanolic acid and pharmaceutical preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102926552A CN102133219A (en) | 2010-09-27 | 2010-09-27 | Anti-cervical cancer effect of oleanolic acid and pharmaceutical preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102133219A true CN102133219A (en) | 2011-07-27 |
Family
ID=44293232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102926552A Pending CN102133219A (en) | 2010-09-27 | 2010-09-27 | Anti-cervical cancer effect of oleanolic acid and pharmaceutical preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102133219A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013079024A1 (en) | 2011-12-01 | 2013-06-06 | 杭州本生药业有限公司 | Oleanolic acid amidate derivatives, preparation methods and uses thereof |
| WO2013079018A1 (en) | 2011-12-01 | 2013-06-06 | 杭州本生药业有限公司 | 2-substituted oleanolic acid derivative, method preparing for same, and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1704062A (en) * | 2004-05-26 | 2005-12-07 | 杭州民生药业集团有限公司 | Sustained release tablet of oleanolic acid and its preparation method |
-
2010
- 2010-09-27 CN CN2010102926552A patent/CN102133219A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1704062A (en) * | 2004-05-26 | 2005-12-07 | 杭州民生药业集团有限公司 | Sustained release tablet of oleanolic acid and its preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 耿传营等: "中药单体齐墩果酸、姜黄素和大蒜素增强宫颈癌Me180细胞放疗敏感性", 《中华放射医学与防护杂志》, vol. 29, no. 5, 31 October 2009 (2009-10-31), pages 472 - 475 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013079024A1 (en) | 2011-12-01 | 2013-06-06 | 杭州本生药业有限公司 | Oleanolic acid amidate derivatives, preparation methods and uses thereof |
| WO2013079018A1 (en) | 2011-12-01 | 2013-06-06 | 杭州本生药业有限公司 | 2-substituted oleanolic acid derivative, method preparing for same, and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102166260B (en) | Clove extract with tumor resisting effect and pharmaceutical preparation thereof | |
| CN102895538A (en) | Preparation technology and production method for integrated new formulation of white tiger and genseng decoction | |
| CN102133219A (en) | Anti-cervical cancer effect of oleanolic acid and pharmaceutical preparation thereof | |
| CN104337823B (en) | Pharmaceutical composition for inhibiting tumor | |
| CN101732389A (en) | Chinese medicinal composition for treating traumatic injury and promoting fracture healing and preparation method thereof | |
| CN102151275A (en) | Pancreatic cancer-resisting effect of oleanolic acid and pharmaceutical preparation of oleanolic acid | |
| CN111265599A (en) | Application of lycopene and grape seed composition in preparation of medicine for treating arthritis | |
| CN102309487A (en) | The antihepatocarcinoma effect of piperine and pharmaceutical preparation thereof | |
| CN102114022A (en) | Application of oleanolic acid in resisting colon cancer and pharmaceutical preparations thereof | |
| CN102370901A (en) | Pharmaceutical composition for treating nephrosis and preparing process thereof | |
| CN102114023A (en) | Oleanolic acid with anti-oophoroma action and pharmaceutical preparations thereof | |
| CN102114021A (en) | Application of oleanolic acid in resisting breast cancer and pharmaceutical preparations thereof | |
| CN102106860A (en) | Anti-liver-cancer effect of Oleanolic acid and pharmaceutic preparation | |
| US9943560B2 (en) | Medical compositions containing liquorice extracts with synergistic effect | |
| CN102114059A (en) | Nutmeg extract with antitumor effect and medicinal preparation thereof | |
| CN102091078A (en) | Maslinic acid anti-hepatocarcinoma effect and maslinic acid medicinal preparation | |
| CN102106858A (en) | Anti-cervical carcinoma effect of maslinic acid and medicinal preparation thereof | |
| CN102106859A (en) | Breast cancer-resisting function and pharmaceutical preparation of maslinic acid | |
| CN102106861A (en) | Anti-colon cancer effect of maslinic acid and medicinal preparation thereof | |
| CN102151276A (en) | Pancreatic cancer resistance effect and pharmaceutical preparation of crataegolic acid | |
| CN102309484A (en) | The effect of anti-lung cancer of piperine and pharmaceutical preparation thereof | |
| CN102309485A (en) | The effect of resistive connection intestinal cancer and the pharmaceutical preparation thereof of piperine | |
| CN106237250A (en) | A kind of Chinese medicine composition treating prostatic hyperplasia and capsule thereof and preparation method | |
| CN102225068A (en) | Anti-ovarian cancer effect of maslinic acid and medicinal preparation thereof | |
| CN101940585B (en) | Composition with orientin-2' -O-beta-L-galactoside as main component and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110727 |